Centene’s post-2025 “big reset” is turning into a 2026 margin-led rebound—just as OBBBA rewires Medicaid economics and forces managed care to get leaner, faster.
Overview
Centene enters 2026 in recovery mode after a disruptive 2025 defined by a $6.7B GAAP loss driven primarily by a $6.72B non-cash goodwill impairment tied to a stock-price decline and the passage of the OBBBA—alongside portfolio simplification actions such as divesting remaining Magellan assets. Despite 2025 revenue surging to ~$194.8B, profitability deteriorated as the consolidated HBR climbed to 91.9% on post-PHE Medicaid risk mix worsening, higher behavioral health utilization, and specialty drug pressure. Q1 2026 marked an operational inflection: adjusted EPS of $3.37 materially beat expectations on better-than-feared medical cost trends and aggressive repricing, with revenue up 7.1% YoY to ~$49.94B. Segment performance showed Medicaid HBR improving to 93.1% (third straight quarter of progress), Marketplace stabilizing after ~30%+ premium hikes despite a ~36% membership drop, and Medicare delivering standout HBR (84.9%) with strong PDP growth. The core debate for 2027–2030 is whether Centene can sustain margin restoration while OBBBA structurally tightens Medicaid financing, increases churn via semi-annual redeterminations, and raises administrative burden across the system.